<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9215429</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2408</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Mutat</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Mutat.</journal-id>
<journal-title-group>
<journal-title>Human mutation</journal-title>
</journal-title-group>
<issn pub-type="ppub">1059-7794</issn>
<issn pub-type="epub">1098-1004</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30098107</article-id>
<article-id pub-id-type="pmc">6240360</article-id>
<article-id pub-id-type="doi">10.1002/humu.23611</article-id>
<article-id pub-id-type="manuscript">NIHMS985327</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Exploring Genetic Modifiers of Gaucher Disease: The Next Horizon</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Davidson</surname>
<given-names>Brad A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Hassan</surname>
<given-names>Shahzeb</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garcia</surname>
<given-names>Eric Joshua</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tayebi</surname>
<given-names>Nahid</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sidransky</surname>
<given-names>Ellen</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<aff id="A1"><label>1</label>Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA</aff>
</contrib-group>
<author-notes>
<corresp id="CR1"><label>*</label><bold>Corresponding author:</bold> Ellen Sidransky M.D., Chief, Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, NIH, Building 35A, Room 1E623, 35 Convent Drive, MSC 3708, Bethesda, MD 20892-3708, Phone: 301-451-0901 or 301-496-0373, Fax: 301-402-6438, <email>sidranse@mail.nih.gov</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>24</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>39</volume>
<issue>12</issue>
<fpage>1739</fpage>
<lpage>1751</lpage>
<!--elocation-id from pubmed: 10.1002/humu.23611-->
<abstract id="ABS1">
<p id="P1">Gaucher disease is an autosomal recessive lysosomal storage disorder resulting from mutations in the gene <italic>GBA1</italic> that lead to a deficiency in the enzyme glucocerebrosidase<italic>.</italic> Accumulation of the enzymeâ€™s substrates, glucosylceramide and glucosylsphingosine, result in symptoms ranging from skeletal and visceral involvement to neurological manifestations. Nonetheless, there is significant variability in clinical presentations amongst patients, with limited correlation between genotype and phenotype. Contributing to this clinical variation are genetic modifiers that influence the phenotypic outcome of the disorder. In this review, we explore the role of genetic modifiers in Mendelian disorders, and describe methods to facilitate their discovery. In addition, we provide examples of candidate modifiers of Gaucher disease, explore their relevance in the development of potential therapeutics, and discuss the impact of <italic>GBA1</italic> and modifying mutations on other more common diseases like Parkinson disease. Identifying these important modulators of Gaucher phenotype may ultimately unravel the complex relationship between genotype and phenotype and lead to improved counseling and treatments.</p>
</abstract>
<kwd-group>
<kwd>genetic modifiers</kwd>
<kwd>Mendelian disorders</kwd>
<kwd>Gaucher disease</kwd>
<kwd>genotype-phenotype correlation</kwd>
<kwd>glucocerebrosidase</kwd>
<kwd>Parkinson disease</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>